Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07169149

Study About Drug Resistance of Mycobacterium Tuberculosis

Tuberculosis is a major cause of ill health and one of the leading causes of death worldwide. Early, rapid and accurate diagnosis of all TB patients and prompt treatment with any form of drug-susceptible or drug resistant TB is fundamental. Identifying the pattern of drug resistance will ensure that the most effective therapy can be selected. The aim of this study is to assess the prevalence and patterns of drug resistance of mycobacterium tuberculosis and to detect the possible risk factors associated with resistant cases.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Pulmonary and Extra- Pulmonary Tuberculosis (TB) Actinomycetales Infections Bacterial Infections Bacterial Infections and Mycoses Gram-Positive Bacterial Infections Infections Mycobacterium Infections Tuberculosis Tuberculosis, Extrapulmonary

Age range

12 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • geneXpert positive patients in pulmonary and extrapulmonary cases

Exclusion criteria

  • age below 12 years

Treatment and study plan

Primary outcomes

  1. Detection of number of cases resistant to Rifampicin and other anti- TB drugs

    Time frame: within 6 months of starting treatment

    Using of GeneXpert (MTB/RIF) and Xpert (MTB/XDR) assays to detect resistance to Rifampicin and other anti -TB drugs among TB positive cases

Secondary outcomes

  1. Detection of common Risk factors associated with resistant cases

    Time frame: within 6 months of starting treatment coarse

    collection of (in common) data among cases to detect risk factors associated with drug resistance e.g is drug resistance more common in diabetic patients?, is resistance more common among drug addict patients? , also is there common co-morbid conditions among resistant cases

Study contacts

Contact information is provided by the study sponsor or research team.

Omnia Abdelazeem Zahran

CONTACT

[email protected]

+2 01113328989

Sponsors and collaborators

Lead sponsor

Sohag University

Other

Registry information

Official study title

Study of the Prevalence and Patterns of Drug Resistance of Mycobacterium Tuberculosis Using GeneXpert (MTB/RIF) and Xpert (MTB/XDR) Assays

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Sep 11, 2025
Registry last updated
Sep 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.